Categories Cancer Treatment
Relevance: Medium-High
Most relevant for: People with advanced HER2-positive cancer
Topic: The drug Enhertu is FDA-approved for any advanced or metastatic HER2-positive tumors
The FDA granted accelerated approval of Enhertu for people with any HER2-positive tumor that is metastatic or cannot be surgically removed. Eligible patients must have had previous treatment such as chemotherapy or hormone therapy. (Posted 7/19/24)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium-High
Most relevant for: Cancer patients
Topic: Experts call for early palliative care for cancer patients
People with cancer need support and care not only at the end of life but from the time of diagnosis. At the 2024 American Society of Clinical Oncology (ASCO) annual meeting, the organization’s president urged cancer healthcare professionals to make palliative care central to cancer treatment. (Posted 7/17/24)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium-High
Most relevant for: People with a BRCA1 or BRCA2 mutation who are considering breast MRI screening
Study: Yearly breast MRI screening improves outcomes for women with inherited BRCA mutations
An international research study of yearly breast MRI screening among women with BRCA1 and BRCA2 gene mutations found that BRCA1 carriers who had MRI screenings were less likely to die of breast cancer than those who did not. Additional studies with more BRCA2 mutation carriers are needed to determine if yearly breast MRIs reduce deaths from breast cancer in this group. (Posted 6/24/24)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium-High
Most relevant for: People with early-stage HER2-postive breast cancer
Update: Targeted therapy for early-stage HER2-positive breast cancer continues to show benefit
People with early-stage HER2-positive breast cancer benefit from targeted therapy. This update includes new data on survival and the length of time without cancer returning. (Posted 6/20/24)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium-High
Most relevant for: People with ovarian cancer.
Update: News from the FDA: New ovarian cancer treatment and imaging drug
The FDA recently approved a new treatment for some people with ovarian cancer. The FDA also approved a new imaging drug that can help surgeons find and remove ovarian cancer. (Posted 5/30/24)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium-High
Most relevant for: People with colorectal cancer
Update: News from the FDA - Two new metastatic colorectal cancer treatments
The FDA recently approved two new treatments for metastatic colorectal cancer. (Posted 3/22/24)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium-High
Most relevant for: People with triple-negative breast cancer
Topic: Progress in the treatment of triple-negative breast cancer
During the December 2023 San Antonio Breast Cancer Symposium, Dr. Melinda Telli presented a summary of research that has led to better treatments for triple-negative breast cancer (TNBC). These treatments now include drugs called targeted therapies and immunotherapies for both early and late stages of TNBC. (Posted 3/19/24)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium
Most relevant for: People with HR-positive and HER2-negative metastatic breast cancer. People with silicone breast implants. People considering thermography screening
Update: News from the FDA– new breast cancer treatment, thermography warning and implant screening updates
This XRAY review is a summary of FDA breast cancer updates from July to December 2023. This includes a new drug approval and two consumer updates. (Posted 2/21/24)
Este artículo está disponible en español.
READ MORE ›
Relevance: Medium-High
Most relevant for: People with hormone receptor (HR)-positive or HER2-negative breast cancer that has spread outside the breast tissue.
Update: New drug combination for the second treatment of some HR-positive advanced breast cancers
The FDA approved Truqap plus Faslodex for the treatment of metastatic hormone receptor-positive (HR-positive), HER2-negative breast cancer that returned or worsened after treatment with hormone therapy. The approval is for treating cancers in people whose tumors had a mutation in one of three genes. For people with one of these mutations, Truqap improved the time until their cancer came back or got worse. (Posted 2/9/24)
Este artículo está disponible en español.
READ MORE ›
Relevance: High
Most relevant for: People with advanced endometrial cancer
Study: Immunotherapy improves outcomes of advanced endometrial cancer
Standard treatment for advanced endometrial cancer may soon change. A study found that people with advanced or recurrent endometrial cancer who received immunotherapy with chemotherapy had better outcomes than those who had chemotherapy alone. (Posted 12/4/23)
Este artículo está disponible en español.
READ MORE ›